Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Mayo Clinic1 site in 1 country60 target enrollmentMay 1, 2016

ConditionsAmnestic Symptoms Atypical Alzheimer's Disease Logopenic Progressive Aphasia (LPA)Posterior Cortical Atrophy (PCA)Alzheimer Disease Alzheimer Disease, Early Onset Amnestic Disorder Amnestic Mild Cognitive Disorder

InterventionsF-18 AV 1451 C-11 PiB

DrugsF-18 AV 1451 C-11 PiB

Overview

Phase: Not Applicable
Intervention: F-18 AV 1451
Conditions: Amnestic Symptoms
Sponsor: Mayo Clinic
Enrollment: 60
Locations: 1
Primary Endpoint: Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
Status: Active, not recruiting
Last Updated: 23 days ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.

Registry

clinicaltrials.gov

Start Date

May 1, 2016

End Date

March 1, 2027

Last Updated

23 days ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Mayo Clinic

Responsible Party

Principal Investigator

Jennifer Whitwell

Associate Professor of Radiology

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

•Over the age of 21
•Must have an informant who will be able to provide independent evaluation of functioning
•English is primary language
•All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
•All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
•All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain

Exclusion Criteria

•If you have had a stroke or tumor that could explain your symptoms
•Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study
•Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded
•Subjects will be excluded if they have poor vision (20/400)
•Women that are pregnant or post-partum and breast-feeding will be excluded
•Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome
•Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)